+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Neuropathic Pain Drug Market Research Report by Type, by Treatment, by Indication, by Diagnosis, by Distribution, by End User - United States Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 5123703
  • Report
  • July 2020
  • Region: United States
  • 90 pages
  • 360iResearch™
UP TO OFF
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • MORE
The United States Neuropathic Pain Drug Market is projected to grow with a significant CAGR in the forecast period. Economic development and substantial infrastructure development have constituted regional revenue generation. Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities. Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the United States Neuropathic Pain Drug Market.

Market Segmentation & Coverage:

This research report categorizes the Neuropathic Pain Drug market to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Neuropathic Pain Drug Market studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

Based on Treatment, the Neuropathic Pain Drug Market studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type further studied across Ibuprofen and Naproxen.

Based on Indication, the Neuropathic Pain Drug Market studied across Diabetic Neuropathy and Spinal Stenosis.

Based on Diagnosis, the Neuropathic Pain Drug Market studied across Blood Tests and Imaging Physical Examination. The Imaging Physical Examination further studied across CT, Electromyography, and MRI.

Based on Distribution, the Neuropathic Pain Drug Market studied across Online Pharmacies and Retail Pharmacies & Drug Stores.

Based on End User, the Neuropathic Pain Drug Market studied across Clinics and Hospitals.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the United States Neuropathic Pain Drug Market including Bristol-Myers Squibb and Company, Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., and Pfizer Inc..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Neuropathic Pain Drug Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Neuropathic Pain Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Neuropathic Pain Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Neuropathic Pain Drug Market?
4. What is the competitive strategic window for opportunities in the United States Neuropathic Pain Drug Market?
5. What are the technology trends and regulatory frameworks in the United States Neuropathic Pain Drug Market?
6. What are the modes and strategic moves considered suitable for entering the United States Neuropathic Pain Drug Market?
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome

3. Executive Summary
3.1. Market Outlook
3.2. Type Outlook
3.3. Treatment Outlook
3.4. Indication Outlook
3.5. Diagnosis Outlook
3.6. Distribution Outlook
3.7. End User Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. United States Neuropathic Pain Drug Market, By Type
6.1. Introduction
6.2. Phantom Limb Pain
6.3. Post Herpetic Neuralgia
6.4. Post-traumatic Neuropathy
6.5. Trigeminal Neuralgia

7. United States Neuropathic Pain Drug Market, By Treatment
7.1. Introduction
7.2. Antidepressant Drugs Type
7.2.1. Serotonin Noradrenaline
7.2.2. Tricyclic Antidepressants
7.3. Medication Type
7.4. Multimodal Therapy
7.5. NSAIDs Type
7.5.1. Ibuprofen
7.5.2. Naproxen

8. United States Neuropathic Pain Drug Market, By Indication
8.1. Introduction
8.2. Diabetic Neuropathy
8.3. Spinal Stenosis

9. United States Neuropathic Pain Drug Market, By Diagnosis
9.1. Introduction
9.2. Blood Tests
9.3. Imaging Physical Examination
9.3.1. CT
9.3.2. Electromyography
9.3.3. MRI

10. United States Neuropathic Pain Drug Market, By Distribution
10.1. Introduction
10.2. Online Pharmacies
10.3. Retail Pharmacies & Drug Stores

11. United States Neuropathic Pain Drug Market, By End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals

12. Competitive Strategic Window
12.1. Introduction
12.2. Competitive Strategic Window, by Type
12.3. Competitive Strategic Window, by Treatment
12.4. Competitive Strategic Window, by Indication
12.5. Competitive Strategic Window, by Diagnosis
12.6. Competitive Strategic Window, by Distribution
12.7. Competitive Strategic Window, by End User

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Bristol-Myers Squibb and Company
14.2. Eli Lily and Company
14.3. GlaxoSmithKline PLC
14.4. Johnson & Johnson Services Inc.
14.5. Pfizer Inc.

15. Appendix
15.1. Discussion Guide
15.2. Edition Details
15.3. License Details
15.4. Pricing Details

LIST OF FIGURES
FIGURE 1. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: RESEARCH EXECUTION
FIGURE 3. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2019 VS 2025 (USD MILLION)
FIGURE 4. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 5. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2019 VS 2025 (USD MILLION)
FIGURE 6. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2019 VS 2025 (USD MILLION)
FIGURE 7. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2019 VS 2025 (USD MILLION)
FIGURE 8. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (USD MILLION)
FIGURE 9. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2019 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES NEUROPATHIC PAIN DRUG MARKET, BY TYPE
FIGURE 11. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2025 (USD MILLION)
FIGURE 12. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: MARKET DYNAMICS
FIGURE 13. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2019 VS 2025 (USD MILLION)
FIGURE 14. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2019 VS 2025 (USD MILLION)
FIGURE 15. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2019 VS 2025 (USD MILLION)
FIGURE 16. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2019 VS 2025 (USD MILLION)
FIGURE 17. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2019 VS 2025 (USD MILLION)
FIGURE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2019 VS 2025 (USD MILLION)
FIGURE 19. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TYPE, 2025 (USD MILLION)
FIGURE 20. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TREATMENT, 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 (USD MILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIAGNOSIS, 2025 (USD MILLION)
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION, 2025 (USD MILLION)
FIGURE 24. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY END USER, 2025 (USD MILLION)
FIGURE 25. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 26. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: MARKET SHARE ANALYSIS

LIST OF TABLES
TABLE 1. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2017-2025 (USD MILLION)
TABLE 2. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PHANTOM LIMB PAIN, 2017-2025 (USD MILLION)
TABLE 3. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST HERPETIC NEURALGIA, 2017-2025 (USD MILLION)
TABLE 4. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-TRAUMATIC NEUROPATHY, 2017-2025 (USD MILLION)
TABLE 5. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRIGEMINAL NEURALGIA, 2017-2025 (USD MILLION)
TABLE 6. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2017-2025 (USD MILLION)
TABLE 7. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SEROTONIN NORADRENALINE, 2017-2025 (USD MILLION)
TABLE 8. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2017-2025 (USD MILLION)
TABLE 9. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MEDICATION TYPE, 2017-2025 (USD MILLION)
TABLE 10. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MULTIMODAL THERAPY, 2017-2025 (USD MILLION)
TABLE 11. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NSAIDS TYPE, 2017-2025 (USD MILLION)
TABLE 12. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IBUPROFEN, 2017-2025 (USD MILLION)
TABLE 13. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY NAPROXEN, 2017-2025 (USD MILLION)
TABLE 14. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, 2017-2025 (USD MILLION)
TABLE 15. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPINAL STENOSIS, 2017-2025 (USD MILLION)
TABLE 16. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY BLOOD TESTS, 2017-2025 (USD MILLION)
TABLE 17. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY IMAGING PHYSICAL EXAMINATION, 2017-2025 (USD MILLION)
TABLE 18. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY CT, 2017-2025 (USD MILLION)
TABLE 19. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ELECTROMYOGRAPHY, 2017-2025 (USD MILLION)
TABLE 20. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY MRI, 2017-2025 (USD MILLION)
TABLE 21. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ONLINE PHARMACIES, 2017-2025 (USD MILLION)
TABLE 22. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, 2017-2025 (USD MILLION)
TABLE 23. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY CLINICS, 2017-2025 (USD MILLION)
TABLE 24. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS, 2017-2025 (USD MILLION)
TABLE 25. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: SCORES
TABLE 26. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: BUSINESS STRATEGY
TABLE 27. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: PRODUCT SATISFACTION
TABLE 28. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: RANKING
TABLE 29. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: MERGER & ACQUISITION
TABLE 30. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 31. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 32. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: INVESTMENT & FUNDING
TABLE 33. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 34. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: EDITION DETAILS
TABLE 35. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: LICENSE DETAILS
TABLE 36. UNITED STATES NEUROPATHIC PAIN DRUG MARKET: PRICING DETAILS
Note: Product cover images may vary from those shown
3 of 3
  • Bristol-Myers Squibb and Company
  • Eli Lily and Company
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Adroll
adroll